Retinal drug targets;Cibles rétiniennes d'action des médicaments

Annales Pharmaceutiques Francaises

Volumn 69, Issue 2, 2011, Pages 124-130

  Behar Cohen, F ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Glucocorticoids; Retina; Targets; Toxicity

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ARTICLE; DRUG TARGETING; HUMAN; RETINA; RETINA DISEASE; UVEA;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD-RETINAL BARRIER; HUMANS; OCULAR PHYSIOLOGICAL PHENOMENA; PHARMACEUTICAL PREPARATIONS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINA; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953027220     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2011.01.003     Document Type: Article

References (33)

1. Challa J.K., Gillies M.C., Penfold P.L., Gyory J.F., Hunyor A.B., Billson F.A. Exsudative macular degeneration and intravitreal triamcinolone: 18 month follow-up. Aust N Z J Ophthalmol 1998, 26:277-281.
2. Jonas J.B., Akkoyun I., Budde W.M., Kreissig I., Degenring R.F. Intravitreal reinjection of triamcinolone for exsudative age-related macular degeneration. Arch Ophthalmol 2004, 122:218-222.
3. Andrade R.E., Muccioli C., Farah M.E., et al. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004, 137:572-574.
4. Karacorlu M., Mudun B., Ozdemir H., et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am J Ophthalmol 2004, 138:289.
5. Massin P., Audren F., Haouchine B., et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004, 111:218-224.
6. Rosenfeld P.J., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1419-1431.
7. Schmidt-Erfurth U., Tano Y., Wolf S Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010, 94(1):2-13.
8. Kiernan D.F., Mieler W.F. The use of intraocular corticosteroids. Expert Opin Pharmacother 2009, 10(15):2511-2525.
9. Carnahan M.C., Goldstein D.A. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000, 11(6):478-483.
10. Torriglia A., Valamanesh F., Behar-Cohen F. On the retinal toxicity of intraocular glucocorticoids. Biochem Pharmacol 2010, 80:1878-1886.
11. Grossmann C., Scholz T., Rochel M., Bumke-Vogt C., Oelkers W., Pfeiffer A.F.H., et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 2004, 151(3):397-406.
12. Funder J.W. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005, 93(2-5):121-125.
13. Fève B., Claës A., Viengchareun S., Lombès M., Zennaro M. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21(9):2185-2194.
14. Farman N., Maubec E., Poeggeler B., Klatte J.E., Jaisser F., Paus R. The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. Exp Dermatol 2010, 19(2):100-107.
15. Joëls M., Karst H., DeRijk R., de Kloet E.R. The coming out of the brain mineralocorticoid receptor. Trends Neurosci 2008, 31(1):1-7.
16. Rauz S., Walker E.A., Hughes S.V., Coca-Prados M., Hewison M., Murray P.I., et al. Serum and glucocorticoid-regulated kinase isoform-1 and epithelial sodium channel subunits in human ocular ciliary epithelium. Invest Ophthalmol Vis Sci 2008, 49(5):1886-1897.
17. Suzuki T., Sasano H., Kaneko C., Ogawa S., Darnel A.D., Krozowski Z.S. Immunohistochemical distribution of 11 beta-hydroxysteroid dehydrogenase in human eye. Mol Cell Endocrinol 2001, 173(1-2):121-125.
18. Mirshahi M., Nicolas C., Mirshahi A., Hecquet C., d'Hermies F., Faure J.P., et al. The mineralocorticoid hormone receptor and action in the eye. Biochem Biophys Res Commun 1996, 219(1):150-156.
19. Zmijewski M.A., Sharma R.K., Slominski A.T. Expression of molecular equivalent of hypothalamic-pituitary-adrenal axis in adult retinal pigment epithelium. J Endocrinol 2007, 193(1):157-169.
20. Wilkinson-Berka J.L., Tan G., Jaworski K., Miller A.G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009, 104(1):124-133.
21. Zhao M., Valamanesh F., Celerier I., Savoldelli M., Jonet L., Jeanny J., et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J 2010, 24:3405-3415.
22. Carvounis P.E., Abd-El-Barr M.M., Albini T.A., Holz E.R. Effects of intravitreous injection of preserved and non-preserved triamcinolone in rabbit retina. Arch Ophthalmol 2006, 124:1666.
23. Kozak I., Cheng L., Falkenstein I., Tammewar A.M., Freeman W.R. Evaluation of subretinal triamcinolone acetonide in patients with exudative age-related macular degeneration. J Ocul Pharmacol Ther 2007, 23:46-53.
24. Valamanesh F., Berdugo M., Sennlaub F., Savoldelli M., Goumeaux C., Houssier M., et al. Effects of triamcinolone acetonide on vessels of the posterior segment of the eye. Mol Vis 2009, 15:2634-2648.
25. Valamanesh F., Torriglia A., Savoldelli M., Gandolphe C., Jeanny J.C., BenEzra D., et al. Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Mol Vis 2007, 13:1746-1757.
26. Penn J.S., Madan A., Caldwell R.B., Bartoli M., Caldwell R.W., Hartnett M.E. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008, 27(4):331-371.
27. Witmer A.N., Vrensen G.F.J.M., Van Noorden, Schlingemann R.P. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003, 22:1-29.
28. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331(22):1480-1487.
29. Saint-Geniez M., Maharaj A.S., Walshe T.E., Tucker B.A., Sekiyama E., Kurihara T., et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PA. PLoS One 2008, 3(11):e3554. [Epub 2008 Nov 3].
30. Miki A., Miki K., Ueno S., Wersinger D.M., Berlinicke C., Shaw G.C., et al. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. J Cell Physiol 2010, 224(1):262-272.
31. Saint-Geniez M., Kurihara T., Sekiyama E., Angel E., Maldonado, Patricia A., et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. PNAS 2009, 106(44):18751-18756. [published ahead of print October 19].
32. Rakic J.M., Lambert V., Devy L., Luttun A., Carmeliet P., Claes C., et al. Placenta growth factor, a member of the VEGF family, contribute to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44(7):318693.
33. Miyamoto N., de Kozak Y., Jeanny J.C., Glotin A., Mascarelli F., Massin P., et al. (2007) Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 2006, 50(2):461-470.